Buying its own future output: the company is spending now to own more of the value it already helps create
The model's full reasoning — Q1 2023 call → NOWe need to determine if management describes the company currently moving itself further up or down its own value chain, taking ownership or direct control of a step that someone else used to perform, and that this move is already being executed and changing what the company earns or can do. Let's analyze the transcript. The company is Inogen, a portable oxygen concentrator (POC) maker. They have channels: rental (prescriber channel), B2B (selling to HMEs), DTC (direct-to-consumer), and international B2B. Key points from the call: - They discuss their channel strategy: "Our channel strategy was designed to improve our ability to serve patients at the point of diagnosis and prescription through Inogen and HME partners while refining our DTC model to meet the needs of patients who desire to switch to POC-based therapy later in their disease management journey." - They talk about rental revenue growth, prescriber channel, securing coverage from private payers. - They mention B2B channel dynamics, HMEs focusing on margin, etc. - They talk about DTC business: "we have remained focused on scaling the new disciplines in DTC as we work towards achieving the right growth and productivity while optimizing our cost basis." They decreased number of sales reps but increased productivity per rep. - They mention launching Rove 6 in Europe, Rove 4 in U.S. later. Is there any description of taking over a step previously done by others? For example, are they moving from selling through distributors to selling directly? They already have DTC, so that's not new. They have rental channel which is direct to patients via prescribers. They also sell to HMEs (B2B). They are not taking over HME functions? They are expanding rental revenue, which is direct to patients, but that's been their model. They are not acquiring HMEs or taking over distribution. They mention "securing coverage from more private payers" - that's about reimbursement, not value chain. They mention "we recently added two large private health care payers" - that's about insurance coverage. They talk about "our ambition to serve a larger COPD population and broaden our portfolio" - that's product expansion. No mention of internalizing manufacturing, supply chain, distribution, or any step previously outsourced.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| KMDA | Kamada Ltd. | Q2 2023 | 2023-08-16 | B+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| SLQT | SelectQuote, Inc. | Q2 2022 | 2022-02-07 | F |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| KNDI | Kandi Technologies Group, Inc. | Q2 2021 | 2021-08-09 | F |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| PRPO | Precipio, Inc. | Q3 2018 | 2018-11-19 | D |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| KOP | Koppers Holdings Inc. | Q2 2018 | 2018-08-12 | C+ |
| XOM | Exxon Mobil Corporation | Q2 2018 | 2018-07-27 | C |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
| GES | Guess?, Inc. | Q1 2017 | 2016-05-25 | F |
FLEX · Q1 2018 → YESThe question is about whether Flex Ltd is currently moving itself further up or down its own value chain by taking ownership or control of a step that someone else used to perform. YES The transcript shows Flex is actively internalizing a previously external step in the shoe manufacturing value chain by taking ownership of automation, process redesign, and end-to-end production for Nike. Management describes this as an ongoing, real-time execution: “we’re vertically integrating technologies,” “rethinking all of the whole supply process we’re applying automation technologies,” “we’ve manufactured over 1 million pairs,” and “we took over the facility in September” for Bose, with the Nike factory transition “complete by October.” They explain the value capture: the company now keeps margin it previously paid away, controls quality, cost, supply, and timing previously constrained by a counterparty, and serves customers it could not reach through the old chain. While acknowledging the ramp is early (losses persist through Q2, breakeven expected by year-end), the move is already changing what Flex earns and can do, not merely planned or contemplated. This meets all three required elements.
XOM · Q2 2018 → YESThe question is about whether ExxonMobil is currently moving itself further up or down its own value chain by taking ownership or control of a step that someone else used to perform. YES The transcript shows ExxonMobil actively internalizing logistics and supply-chain steps that previously required external partners or intermediaries. Neil Chapman explicitly states they “will get engaged in the connectivity between the Permian and our Gulf Coast refining and chemical assets,” with equity participation in logistics, the Wink terminal acquisition (closed late 2017), 11 active completion crews, and a signed letter of intent for a 1 million bpd long-haul crude pipeline. These moves are already producing results: Gulf Coast refineries are “already processing our production levels and more, capturing the benefits of disadvantaged feed cost.
KMDA · Q2 2023 → YESThe question is about whether management describes the company currently moving itself further up or down its own value chain, taking ownership of a step that someone else used to perform, and that th...YES The transcript shows management describing the 2021 acquisition of the Beaumont plasma collection center as the company's entry into U.S. plasma collection, with the explicit goal of becoming a "fully integrated specialty plasma product company." They state they are "successfully expanding" capacity at the first center (already acquired and operational) and plan to open the second in Houston in early 2024. This is presented as an active, ongoing move to internalize plasma collection that previously depended on external suppliers.